Atossa TherapeuticsATOS +3.92%26 Debt-to-EBITDA is 0.00 as of Mar. 2026. GuruFocus rates ATOS with a GF Score™ of 26/100. The stock has 2 warning signs investors should review. Among 291 Biotechnology companies, Atossa Therapeutics ranks worse than 343642.27% on this metric.
Debt-to-EBITDA measures a company's ability to pay off its debt.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
The historical rank and industry rank for Atossa Therapeutics's Debt-to-EBITDA or its related term are showing as below:
ATOS's Debt-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 1.16 * Ranked among companies with meaningful Debt-to-EBITDA only.
A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.
According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.
Atossa Therapeutics Debt-to-EBITDA Related Terms
Atossa Therapeutics Debt-to-EBITDA Historical Data
* Premium members only.
The historical data trend for Atossa Therapeutics's Debt-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ATOS vs QNCX, ZIVO, KTTA: Debt-to-EBITDA Comparison
For the Biotechnology subindustry, Atossa Therapeutics's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Atossa Therapeutics Debt-to-EBITDA vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Atossa Therapeutics's Debt-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Atossa Therapeutics's Debt-to-EBITDA falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data,
the EBITDA data used here is four times the quarterly (Mar. 2026) EBITDA data.
Atossa Therapeutics (ATOS) has a Debt-to-EBITDA of 0.00 as of Mar. 2026. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Atossa Therapeutics. According to the industry distribution chart, Atossa Therapeutics ranks #999999 out of 291 companies in the Biotechnology industry.
Is Atossa Therapeutics' Debt-to-EBITDA too high?
Atossa Therapeutics' current Debt-to-EBITDA is 0.00. Based on the distribution chart, Atossa Therapeutics ranks #999999 out of 291 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Atossa Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Atossa Therapeutics' Debt-to-EBITDA compare to QNCX and ZIVO?
According to the Biotechnology industry distribution chart, Atossa Therapeutics ranks #999999 out of 291 companies for Debt-to-EBITDA. This places Atossa Therapeutics in the lower half of its industry. The industry median Debt-to-EBITDA is 1.16. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-EBITDA for a Biotechnology company?
The median Debt-to-EBITDA among Biotechnology companies is 1.16, based on 291 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-EBITDA significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-EBITDA mean?
A high Debt-to-EBITDA can signal that a stock is expensive relative to its fundamentals. Debt-to-EBITDA ratio represents the ratio of total debt to total earnings before interest, taxes, depreciation and amortization. View historical data on Atossa Therapeutics. For the Biotechnology industry, the median Debt-to-EBITDA is 1.16 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Atossa Therapeutics's current Debt-to-EBITDA is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Atossa Therapeutics stock overvalued right now?
Atossa Therapeutics (ATOS) has a current Debt-to-EBITDA of 0.00. The current Debt-to-EBITDA is 0.00. Atossa Therapeutics' overall GF Score™ is 26/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-EBITDA calculated?
Debt-to-EBITDA is calculated from a company's financial statements. For Atossa Therapeutics (ATOS), the current Debt-to-EBITDA is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Atossa Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of proprietary medicines for oncology, with a focus on breast cancer and related conditions. The company's lead product candidate, oral (Z)-endoxifen, is a selective estrogen receptor modulator and degrader (SERM/SERD) in Phase 2 clinical development, being evaluated for the treatment and prevention of breast cancer and other indications.
26GF Score
Get the complete analysis for ATOS
Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ATOS has been successfully added to your 
